{"id":47762,"date":"2022-04-01T23:06:31","date_gmt":"2022-04-01T23:06:31","guid":{"rendered":"https:\/\/assignmenttutors.net\/blog\/case-44-medfield-pharma-business-finance-homework-help\/"},"modified":"2022-04-01T23:06:31","modified_gmt":"2022-04-01T23:06:31","slug":"case-44-medfield-pharma-business-finance-homework-help","status":"publish","type":"post","link":"https:\/\/assignmenttutors.net\/blog\/case-44-medfield-pharma-business-finance-homework-help\/","title":{"rendered":"Case 44 medfield pharma | Business & Finance homework help"},"content":{"rendered":"
\n

THE MEDFIELD PHARMA CASE: FIRM VALUATION AND ETHICAL CONSIDERATIONS OF REFORMULATION<\/p>\n

Understand that the Medfield case has 2 major problems: 1) Firm Valuation \u2013 Impact of Patent Loss and Reformulation; 2) Ethical Considerations \u2013 How to Ensure Patients and third-party payees are not hurt<\/p>\n

Organize your paper around the case questions, use them as an organizing device. This will benefit you in several ways: 1) provide a framework for constructing your paper; 2) ensure I (your reader) understand exactly what question you are answering; and 3) ensure you answer every question.<\/p>\n

Use examples from Pfizer, AstraZeneca and other firms in EXHIBIT 3 to substantiate your thought.<\/p>\n

    \n
  1. What is the current value of Medfield as a company? Use the exhibit 4 spreadsheet to calculate the NPV of Medfield. Compare this result to the offer price and provide your reasoning for the difference.<\/li>\n
  2. If we consider the sale of Medfield as the sale of existing assets how does the elimination of R&D, investment in future assets, change the valuation of Medfield? (Using the exhibit 4 spreadsheet distinguish between the NPV value of existing products and R&D)<\/li>\n
  3. What is the value that would be created by a reformulation? Complete and explain the table below.<\/li>\n<\/ol>\n

    2011<\/p>\n

    2012<\/p>\n

    2013<\/p>\n

    2014<\/p>\n

    2015<\/p>\n

    2016<\/p>\n

    2017<\/p>\n

    2018<\/p>\n

    2019<\/p>\n

    2020<\/p>\n

    2021<\/p>\n

    2022<\/p>\n

    2023<\/p>\n

    2024<\/p>\n

    Incremental Research<\/p>\n

    35<\/p>\n

    35<\/p>\n

    Incremental Special Marketing<\/p>\n

    25<\/p>\n

    25<\/p>\n

    25<\/p>\n

    25<\/p>\n

    25<\/p>\n

    Growth<\/p>\n

    2%<\/p>\n

    -50%<\/p>\n

    2%<\/p>\n

    2%<\/p>\n

    2%<\/p>\n

    2%<\/p>\n

    2%<\/p>\n

    2%<\/p>\n

    2%<\/p>\n

    2%<\/p>\n

    -50%<\/p>\n

    -50%<\/p>\n

    -50%<\/p>\n

    New Sales<\/p>\n

    214.77\u00a0<\/p>\n

    Marginal Sales (New Sales \u2013 Original Sales<\/p>\n

    0.00\u00a0<\/p>\n

    New Cost of Sales<\/p>\n

    49.40\u00a0<\/p>\n

    Marginal Cost of Sales<\/p>\n

    0.00\u00a0<\/p>\n

    New Direct Marketing<\/p>\n

    57.99\u00a0<\/p>\n

    Old Direct Marketing<\/p>\n

    57.99\u00a0<\/p>\n

    59.15<\/p>\n

    29.57<\/p>\n

    14.79<\/p>\n

    7.39<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    Marginal Direct Marketing<\/p>\n

    0.00\u00a0<\/p>\n

    New G&A<\/p>\n

    8.59\u00a0<\/p>\n

    Old G&A<\/p>\n

    8.59\u00a0<\/p>\n

    8.76<\/p>\n

    4.38<\/p>\n

    2.19<\/p>\n

    1.10<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    0<\/p>\n

    Marginal G&A<\/p>\n

    0.00\u00a0<\/p>\n

    Marginal Cash Flow pre Tax<\/p>\n

    (60.00)<\/p>\n

    29.52\u00a0<\/p>\n

    14.76\u00a0<\/p>\n

    7.38\u00a0<\/p>\n

    Marginal NOPAT<\/p>\n

    (40.80)<\/p>\n

    20.07\u00a0<\/p>\n

    10.04\u00a0<\/p>\n

    5.02\u00a0<\/p>\n

    NPV<\/strong><\/p>\n

      \n
    1. What factors explain the value created from the reformulation for Fleximat?<\/li>\n
    2. Who reaps the financial benefits?<\/li>\n
    3. Who bears the financial costs?<\/li>\n<\/ol>\n

      ONLY ANSWER ONE OF THE QUESTION 7\u2019S:<\/strong><\/u><\/p>\n

      IF YOU SUPPORT REFORMULATION:<\/p>\n

        \n
      1. What facts would change your mind and cause you to recommend against reformulation?<\/li>\n<\/ol>\n

        IF YOU ARE AGAINST REFORMULATION<\/p>\n

        7. Under what conditions might you be in favor of reformulation?<\/p>\n

          \n
        1. How would you change your thinking if Medfield\u2019s reformulation approach were more substantive (e.g. drug works faster, works longer) than cosmetic?<\/li>\n
        2. Could Medfield use the extra value created by the reformulation to generate new and helpful products?<\/li>\n
        3. When you consider Medfield\u2019s stakeholders, what are the key issues. Choose three from the following list and discuss the key issues.\n
            \n
          1. Shareholders of Medfield<\/li>\n
          2. Patients using the drug<\/li>\n
          3. Third-party payees (Medicare, private insurance companies, etc.)\u00a0<\/li>\n
          4. Government<\/li>\n
          5. Employees of Medfield<\/li>\n
          6. Physicians<\/li>\n<\/ol>\n<\/li>\n
          7. What ethical issues need to be considered in making a reformulation decision? Which are more pressing? Reference the ethics concepts discussed earlier in the semester, include at least one of the Right vs. Wrong explanations presented: Consequences, Duty, or Virtues. Use external references<\/strong> sources to support your discussion of the ethical issues.<\/li>\n
          8. What should Susan Johnson do? \u00a0Explain your choice of a, b, c, or d. If you have another approach, discuss it here.\n
              \n
            1. Don\u2019t pursue the reformulation, but accept takeover offer<\/li>\n
            2. Initiate the reformulation and accept the offer<\/li>\n
            3. Refuse the offer but initiate reformulation<\/li>\n
            4. Refuse the offer and not reformulate<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n

              Your Turnitin Score needs to be 0-30% tops. Try to get it down there. If it is higher, I will read your paper, and see why the score is high but your grade will reflect the score.\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

              THE MEDFIELD PHARMA CASE: FIRM VALUATION AND ETHICAL CONSIDERATIONS OF REFORMULATION Understand that the Medfield case has 2 major problems: 1) Firm Valuation \u2013 Impact of Patent Loss and Reformulation; 2) Ethical Considerations \u2013 How to Ensure Patients and third-party payees are not hurt Organize your paper around the case questions, use them as an […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-47762","post","type-post","status-publish","format-standard","hentry","category-education"],"_links":{"self":[{"href":"https:\/\/assignmenttutors.net\/blog\/wp-json\/wp\/v2\/posts\/47762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/assignmenttutors.net\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/assignmenttutors.net\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/assignmenttutors.net\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/assignmenttutors.net\/blog\/wp-json\/wp\/v2\/comments?post=47762"}],"version-history":[{"count":0,"href":"https:\/\/assignmenttutors.net\/blog\/wp-json\/wp\/v2\/posts\/47762\/revisions"}],"wp:attachment":[{"href":"https:\/\/assignmenttutors.net\/blog\/wp-json\/wp\/v2\/media?parent=47762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/assignmenttutors.net\/blog\/wp-json\/wp\/v2\/categories?post=47762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/assignmenttutors.net\/blog\/wp-json\/wp\/v2\/tags?post=47762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}